Acorda is an early stage life science start with a promising product that is close to reaching the market (III stage of clinical trials). The company is struggling with how to expand its portfolio of molecules to make the business more sustainable. She is faced with the classic choice in licensing, including the fact that the disease is showing at what stage of development, many molecules, and on what terms. "Hide
by Fiona Murray, Marina Kolesnik, Juan Enriquez, Jonathan West Source: Harvard Business School 25 pages. Publication Date: June 24, 2004. Prod. #: 604014-PDF-ENG
Related Case Solutions & Analyses:
Nucor at a Crossroads
Note on Organization Structure
TransMilenio: The Battle Over Avenida Septima
Tata Consultancy Services: Selling Certainty
China: To Float or Not to Float (B): Timeline of Changes Relevant to the Chinese Renminbi
Crash: Viewers Guide
Cocaine Mothers
Hedging an Equity Portfolio
Right Now Technologies
JET VS AMAZON
